Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4049112 | 0.78 | AURKA (0.46) | MEN1ALDH1A1GAAMAPTPKM | |
| SCHEMBL25973301 | 0.75 | POLB (0.38) | MEN1ALDH1A1GAAMAPTPKM | |
| SCHEMBL6899346 | 0.69 | GABRA1 (0.32) | POLB | |
| SCHEMBL16376924 | 0.67 | GABRA1 (0.41) | MEN1ALDH1A1GAAMAPTPKM | |
| SCHEMBL14155861 | 0.65 | TNKS (0.36) | ALDH1A1POLBHDAC4HDAC2HDAC8 | |
| SCHEMBL26323883 | 0.65 | XPO1 (0.39) | MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL26597058 | 0.64 | BRD4 (0.39) | GAAPOLB | |
| SCHEMBL2608378 | 0.64 | ACHE (0.32) | MEN1KMT2AHDAC4HDAC2HDAC8 | |
| SCHEMBL16812507 | 0.64 | GAA (0.34) | MEN1ALDH1A1GAAMAPTKMT2A | |
| SCHEMBL17737467 | 0.64 | TNKS (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210330646-A1 | FASCIN BINDING COMPOUNDS FOR SPINOGENESIS | SPINOGENIX, INC. | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210330646-A1 | FASCIN BINDING COMPOUNDS FOR SPINOGENESIS | FSCN1, SMN1; SMN2, DCX | MEN1 1822/4885ALDH1A1 3791/4885GAA 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.